Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
A year after unveiling its first blood test aimed at spotting the signs of a range of neurodegenerative diseases, Labcorp is ramping up its offerings in that realm with the launch of a new, ...
Labcorp Holdings (NYSE: LH) introduced the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for ...
The clinical services giant Labcorp is rolling out its first blood test to help identify and confirm the signs of multiple neurodegenerative diseases and brain injury, including ALS, dementia and ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo for Labcorp is displayed on a screen on the floor of the NYSE in New York By Deena Beasley (Reuters) - ...
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug ...
Please provide your email address to receive an email when new articles are posted on . Labcorp Diagnostics announced the launch of the first widely accessible blood test that provides direct evidence ...
Hosted on MSN
Labcorp to offer first FDA-cleared blood test for initial Alzheimer’s disease assessment
Labcorp, one of the country’s largest providers of diagnostic medical testing services, announced today that it will offer the only blood test cleared by the U.S. Food and Drug Administration to aid ...
Preeclampsia can be a life-threatening complication of pregnancy, but a new blood test can help predict a woman's risk for the condition while she is in her first trimester, the test's maker said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results